Sign In
Buy AEZS
$5.72
+0 (+0%)
At Close: Nov 13, 2024
Aeterna Zentaris Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market
09:45pm, Wednesday, 05'th Aug 2020
CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeuti
AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
01:00pm, Monday, 03'rd Aug 2020
CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut
CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and dev
CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeu
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
11:05am, Wednesday, 29'th Jul 2020
CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializin
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING
08:05pm, Tuesday, 07'th Jul 2020
Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its pre
Is Aeterna Zentaris (TSE:AEZS) In A Good Position To Deliver On Growth Plans?
11:12am, Friday, 03'rd Jul 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING
02:10am, Thursday, 02'nd Jul 2020
Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of a publi
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY
12:00pm, Thursday, 25'th Jun 2020
Aeterna Zentaris Inc. (AEZS) (AEZS.TO) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entere
Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
12:11pm, Monday, 08'th Jun 2020Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
12:05pm, Monday, 08'th Jun 2020
Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has regained c
Aeterna Zentaris Announced That It Received A Positive Decision From The Listing Qualification Department Of Nasdaq
08:08pm, Thursday, 04'th Jun 2020Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements
08:05pm, Thursday, 04'th Jun 2020
Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has r
Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders
08:45pm, Friday, 15'th May 2020
The individuals noted below were elected as Directors of the Company. The Company would like to welcome Peter Edwards to the Board of Directors. The Company would also like to extend its sincere tha
